Longitudinal magnetic resonance spectroscopy study of metabolite changes over 2 years in relapsing and primary progressive multiple sclerosis treated with ocrelizumab.
MacMillan EL, Russell-Schulz B, Alejo G, Harp C, Cameron B, Winger R, Jia S, Herman A, Kassam J, Waine M, et al.
Mult Scler. 2026 Jun 30:13524585261456964. PMID: 42376811.Abstract
